19,200 Shares in Lantheus Holdings, Inc. $LNTH Purchased by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 19,200 shares of the medical equipment provider’s stock, valued at approximately $1,456,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. M&T Bank Corp bought a new stake in shares of Lantheus in the 4th quarter valued at approximately $370,950,000. Farallon Capital Management LLC raised its holdings in shares of Lantheus by 56.1% in the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after buying an additional 1,950,252 shares in the last quarter. Norges Bank bought a new position in shares of Lantheus during the 4th quarter worth approximately $76,197,000. Freestone Grove Partners LP lifted its position in shares of Lantheus by 4,114.8% during the 4th quarter. Freestone Grove Partners LP now owns 608,526 shares of the medical equipment provider’s stock worth $40,497,000 after buying an additional 594,088 shares during the period. Finally, Summit Street Capital Management LLC acquired a new stake in Lantheus in the 4th quarter valued at $26,997,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Up 0.9%

Shares of LNTH opened at $109.89 on Friday. The company has a market capitalization of $7.15 billion, a P/E ratio of 26.48 and a beta of -0.06. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $111.86. The business’s 50 day simple moving average is $98.00 and its 200-day simple moving average is $81.32. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. During the same period last year, the firm posted $1.53 EPS. The business’s revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 4.49 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on LNTH shares. William Blair reiterated an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. Jefferies Financial Group reissued a “buy” rating and set a $110.00 price objective on shares of Lantheus in a report on Tuesday, March 17th. The Goldman Sachs Group restated a “neutral” rating and issued a $94.00 target price on shares of Lantheus in a research note on Thursday, May 7th. Truist Financial reaffirmed a “buy” rating and issued a $115.00 target price (up from $98.00) on shares of Lantheus in a report on Monday, May 11th. Finally, Citizens Jmp reiterated a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a research report on Monday. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus price target of $101.86.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.